Get the Stockscreener App
8.18
2.38%
+0.19
After Hours:
8.18
Eliem Therapeutics Inc stock is currently priced at $8.18, with a 24-hour trading volume of 134.90K.
It has seen a +2.38% increased in the last 24 hours and a +79.39% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.12 pivot point. If it approaches the $8.37 resistance level, significant changes may occur.
Previous Close:
$7.99
Open:
$7.87
24h Volume:
134.90K
Market Cap:
$215.41M
Revenue:
-
Net Income/Loss:
$-35.12M
P/E Ratio:
-4.8402
EPS:
-1.69
Net Cash Flow:
$-20.60M
1W Performance:
-8.60%
1M Performance:
+79.39%
6M Performance:
+233.88%
1Y Performance:
+182.07%
1D Range:
$7.67
$8.99
52W Range:
$2.34
$11.55
Eliem Therapeutics Inc Stock (ELYM) Company Profile
Name
Eliem Therapeutics Inc
Sector
Industry
Phone
425 276 2300
Address
23515 NE Novelty Hill Road, Suite B221 #125, Redmond
Eliem Therapeutics Inc Stock (ELYM) Latest News
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Update - MarketBeat
MarketBeat
Eliem Therapeutics' Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement – Global Legal ... - Global Legal Chronicle
Global Legal Chronicle
A significant driver of top-line growth: Eliem Therapeutics Inc (ELYM) – Sete News - SETE News
SETE News
Eliem Therapeutics Inc (ELYM) is an excellent investment, but the stock is overvalued/undervalued right now – US Post ... - US Post News
US Post News
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and ... - PR Newswire
PR Newswire
Eliem Therapeutics reaches deal with Tenet Medicines - Puget Sound Business Journal - The Business Journals
The Business Journals
Eliem Therapeutics Inc Stock (ELYM) Financials Data
Eliem Therapeutics Inc (ELYM) Net Income 2024
ELYM net income (TTM) was -$35.12 million for the quarter ending December 31, 2023, a +22.38% increase year-over-year.
Eliem Therapeutics Inc (ELYM) Cash Flow 2024
ELYM recorded a free cash flow (TTM) of -$20.60 million for the quarter ending December 31, 2023, a +44.88% increase year-over-year.
Eliem Therapeutics Inc (ELYM) Earnings per Share 2024
ELYM earnings per share (TTM) was -$1.31 for the quarter ending December 31, 2023, a +23.84% growth year-over-year.
Eliem Therapeutics Inc Stock (ELYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morisset Valerie | EVP, R&D AND CSO |
Sep 20 '23 |
Option Exercise |
0.00 |
20,728 |
14 |
487,460 |
About Eliem Therapeutics Inc
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain; and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
4.29%
2.59%
Cap:
|
Volume (24h):